The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2025 | Current perspectives & future considerations for the integration of ctDNA in HL management
In this video, Sven Borchmann, MD, PhD, University of Cologne, Cologne, Germany, comments on the potential integration of circulating tumor DNA (ctDNA) into the management of Hodgkin lymphoma (HL), highlighting that basic data support its use to identify genotypes and track measurable residual disease (MRD), with prognostic implications. This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yes, so we’ve seen in the past years many different studies looking at circulating tumor DNA in Hodgkin lymphoma, both to understand the genotype of a specific Hodgkin lymphoma case, so before we start treatment, but also to use these markers we identify as MRD markers, minimal residual disease markers, that we can then use to assess response. So I think we have now seen a lot of basic data that backs up the idea and proves that it works in principle both to identify the genotype and second to do MRD tracking in Hodgkin lymphoma and we know it’s prognostic...
Yes, so we’ve seen in the past years many different studies looking at circulating tumor DNA in Hodgkin lymphoma, both to understand the genotype of a specific Hodgkin lymphoma case, so before we start treatment, but also to use these markers we identify as MRD markers, minimal residual disease markers, that we can then use to assess response. So I think we have now seen a lot of basic data that backs up the idea and proves that it works in principle both to identify the genotype and second to do MRD tracking in Hodgkin lymphoma and we know it’s prognostic. We now need to run these clinical trials and identify the clinical situations where it makes most sense to do this and I think there are a couple of interesting ideas out there. We can of course look at these subtypes that have been identified like immune escape Hodgkin lymphoma or oncogene-driven Hodgkin lymphoma or virally driven Hodgkin lymphoma and try to adapt treatment protocols to treat these subgroups specifically or we can escalate or de-escalate treatment based on the MRD response. But how to do that exactly I think is a matter of current debate.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
SB is a founder, shareholder, and managing director of Liqomics and a consultant for Galapagos.
